Compare BMBL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMBL | IMMP |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.0M | 58.2M |
| IPO Year | 2021 | 2012 |
| Metric | BMBL | IMMP |
|---|---|---|
| Price | $3.77 | $0.32 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 14 | 3 |
| Target Price | $4.42 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 3.7M | 1.1M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $965,658,000.00 | N/A |
| Revenue This Year | N/A | $417.85 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.61 | $0.29 |
| 52 Week High | $8.63 | $3.53 |
| Indicator | BMBL | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 14.38 |
| Support Level | $3.21 | N/A |
| Resistance Level | $3.85 | $0.39 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 97.73 | 21.27 |
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.